JPRN-UMIN000016391已完成未知
Phase II study of gefitinib combined with carboplatin/pemetrexed for elderly patients with EGFR mutated advanced non-small cell lung cancer - Gefitinib plus chemotherapy for elderly patient with EGFR-mutated NSCLC
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 75years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Radiographically confirmed interstitial pneumonitis or pulmonary fibrosis. 2) NSCLC harboring T790M mutation 3) No prior gefitinib or pemetrexed treatment as ajuvant/neoajuvant therapy. 4) Symptomatic brain metastases 5) Radiation therapy for primary site. 6) Severe concurrent disease 7) HBs antigen or HBc antibody or HBs antibody positive 8) Patient are treated with steroid continuously 9) Pleural and peritoneal effusion likely to require surgical intervention, or pericardial effusion 10) Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy. 11) Active double cancer 12) Physician concludes that the patient's participation in this trial is inappropriate.
研究者
相似试验
已完成
2 期
PhaseII study of gefitinib combined with cisplatin and pemetrexed in patients with advanced non-squamous, non-small cell lung cancer acquired resistance to first line gefitinib monotherapy.on-small cell lung cancerJPRN-UMIN000005690Division of Thoracic Oncology, Shizuoka Cancer Center30
已完成
不适用
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
已完成
2 期
A phase II trial of gefitinib and concurrent radiation therapy for locally advanced non-small cell lung cancer patients harboring sensitive EGFR mutations.on-small cell lung cancerJPRN-UMIN000003274ational Hospital Organization15
招募中
1 期
A Phase I/II trial to evaluate gefitinib and concurrent postoperative chemoradiation in patients with advanced resectable head and neck cancerACTRN12605000510640peter maccallum Cancer Centre70
已完成
2 期
Phase II study of gefitinib therapy inserted by chemotherapy as first line treatment for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutatioon-small-cell lung cancerJPRN-UMIN000001738Thoracic Medical Oncology, National Cancer Center Hospital33